Elanco Animal Health logo

Elanco Animal Health(ELAN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
STRONG BUY
BUY for 8 days
PROFIT SINCE LAST BUY
+5.81% ▲
LAST CLOSE
$26.78
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ELAN

11/13/2026: ELAN (3-star) is a STRONG-BUY. BUY for 8 days. Simulated Profits (5.81%). Updated daily EoD!

Elanco Animal Health is a major global pure-play animal health company providing essential medicines, vaccines, and parasiticides for both pets and farm animals. The company benefits from a diversified portfolio, strong veterinary relationships, and an innovative pipeline in high-growth pet therapeutics like dermatology and pain management. However, its heavy debt load from past acquisitions and intense competition from larger peers present notable execution and financial risks. Elanco represents a turnaround and growth opportunity suited for risk-tolerant investors willing to monitor debt reduction progress and new product commercialization.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitElanco offers moderate top-line growth driven by new pet product launches, but growth is tempered by mature farm animal segments.
Momentum investorStrong fit while signal remains positiveMomentum appeal depends on positive regulatory approvals, breakout pipeline sales, and upward revisions in quarterly earnings guidance.
Value investorMixed fitWhile shares can look attractive during cyclical pullbacks, the leveraged balance sheet requires careful risk-adjusted valuation assessment.
Dividend investorWeak fitElanco does not pay a dividend, prioritizing cash allocation toward debt reduction and core business reinvestment.
Low-risk investorWeak fitThe company's debt load, exposure to agricultural commodity cycles, and historical equity volatility make it less suitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock frequently reacts sensitively to earnings reports, pipeline updates, and macroeconomic shifts.
Valuation riskMediumValuation depends heavily on successful debt reduction and the commercial performance of recent product launches.
Competition risk (Zoetis and Merck dominance)HighElanco fights for market share against larger, well-funded peers with extensive incumbent portfolios.
Business qualityMedium / highElanco maintains a solid global healthcare franchise, though historical integration and debt burdens affect financial flexibility.
Dividend incomeLow / noneIncome-focused investors receive no cash return through dividends.
Execution riskMedium / highManagement must successfully execute on pipeline commercialization and debt-reduction milestones to expand margins.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 13.39B USD
Price to earnings Ratio -
1Y Target Price 31
Price to earnings Ratio -
1Y Target Price 31
Volume (30-day avg) 5.3M shares
Beta 1.72
52 Weeks Range 19.40 - 27.98
Updated Date 11/15/2026
52 Weeks Range 19.40 - 27.98
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.3

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 67.61%
Avg. Invested days 53
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ELAN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ELAN has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 6.0%) is partially offset by negative earnings growth (-168.6%), moderate revenue growth (+6.2%), weak profitability (net margin -4.9%).

Financial Health Rating

★★★★★
ELAN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 13.9%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ELAN's strongest growth driver at +6.2% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-168.6%, negative) and free-cash-flow growth (-27.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 111.9% and approximately 99.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.21% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Dodge & Cox 13.49%
FMR Inc 11.40%
BlackRock Inc 9.78%
PRIMECAP Management Company 9.09%
T. Rowe Price Investment Management,Inc. 5.75%

Unit Economics (Per $1K Revenue)

★★★★★
ELAN generates approximately $435 of gross profit, $53 of operating income, and $60 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -3.57% (Tax Credit)

Quantitative Style Profile

★★★★★
ELAN has a large-cap, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilityLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Pet HealthTherapeutics, vaccines, and parasiticides for dogs and cats sold through veterinary clinics and retail channels.This is the higher-margin growth engine benefiting from strong pet humanization trends.
Farm AnimalMedications, feed additives, and vaccines for cattle, swine, poultry, and aquaculture production.Provides stable, essential demand linked to global food production and animal protein consumption.
International MarketsGlobal commercial sales spanning Europe, Latin America, and Asia-Pacific.Diversifies revenue streams beyond the US, though exposes results to foreign currency fluctuations.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-06
When Before Market
Estimate 0.2
Actual 0.27

Profitability

Profit Margin -2.86%
Operating Margin (TTM) 7.71%

Management Effectiveness

Return on Assets (TTM) 1.85%
Return on Equity (TTM) -2.2%

Valuation

Trailing PE -
Forward PE 20.62
Enterprise Value 16.63B
Price to Sales(TTM) 2.6
Enterprise Value 16.63B
Price to Sales(TTM) 2.6
Enterprise Value to Revenue 3.23
Enterprise Value to EBITDA 19.4
Shares Outstanding 499.83M
Shares Floating 495.61M
Shares Outstanding 499.83M
Shares Floating 495.61M
Percent Insiders 2.21
Percent Institutions 111.91

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.